Breakthrough treatment could rewrite terminal diagnoses for MND patients
Breakthrough treatment could rewrite terminal diagnoses for MND patients
Imagine a world in which Motor Neurone Disease (MND) – or Amyotrophic lateral sclerosis (ALS) as it is known in the United States – was considered a long-term chronic condition rather than an acute terminal illness.
It could be a possibility following a potential breakthrough by researchers at The University of Queensland (UQ) in Australia, whose search for a cure is as aggressive and relentless as the disease itself.
UQ pharmacologist Professor Trent Woodruff and his team of neuroinflammation scientists have collaborated with the Indian Institute of Technology, The University of Tokyo and Sungkyunkwan University to develop a drug candidate that activates a hard-to-target immune receptor.
The receptor, called C5aR2, is found on the surface of many immune cells.
Professor Woodruff said the drug provided a unique tool to study C5aR2 in detail and opened new possibilities for anti-inflammatory therapies for MND and other neurodegenerative conditions.
“With this knowledge, it’s possible we could have an anti-inflammatory drug treatment for testing in MND patients within 5 years, potentially turning the disease into a long-term chronic condition rather than an acute terminal illness,’’ he said.
“The drug candidate we developed as part of this study, called R8Y, is a molecule that specifically binds to C5aR2.
“This allowed us to see the structure and function of the receptor which led to the discovery that C5aR2 does not behave like most other receptors.
“It is unable to couple to G proteins — a rare and important distinction which explains why it’s been so difficult to target and why its role in inflammation has been so elusive.
“Using the drug we created, our international partners created a model of R8Y bound to the receptor, giving us vital information around how the drug binds to the receptor and how the receptor signals.”
Using this knowledge, the UQ team is now working to develop even better anti-inflammatory drugs for hard-to-treat neurodegenerative diseases like MND, Parkinson’s and Alzheimer’s.
“With this knowledge, it’s possible we could have an anti-inflammatory drug treatment for testing in MND patients within 5 years...’’
What is MND and why is it so hard to treat?
Motor neurons are found in the brain and spinal cord and send messages to activate the muscles in the body.
But in the 140,000 people around the world who are diagnosed with MND each year, messages from the motor neurons gradually stop reaching the muscles, causing them to weaken and eventually stop working.
Some people can live a long life with MND; however, the average life expectancy is 27 months from diagnosis and there is currently no cure.
While a lot of progress has been made in the past 10 years, treatments have remained elusive as MND is a group of diseases with multiple causes, rather than a single cause.
According to FightMND – Australia’s leading organisation focused on funding and promoting research into effective treatments of MND – about 10 per cent of people diagnosed have inherited a genetic mutation from a family member.
However, not everyone with a known gene mutation will develop MND – and of those who are diagnosed, 90 per cent are the only known member in the family to receive a diagnosis.
Environmental factors, such as lifestyle, mechanical and/or electrical trauma, high levels of exercise, or exposure to chemicals, pesticides, or heavy metals, may also play a part in the development of MND.
But with no clear link between someone’s lifestyle or environment and the development of MND, it is not yet possible to identify ways to reduce the risk.
Fighting the Beast takes a global effort
UQ biomedical scientist Associate Professor Richard Clark said the research findings were only possible through the combined expertise at UQ and its international partners.
“This global effort demonstrates the power of cross-disciplinary and cross-border collaboration in tackling complex biomedical challenges,” Dr Clark said.
“With this new ability to selectively target the C5aR2 receptor, we can develop safer, more effective drugs with fewer side effects.’’
The research was funded by FightMND and a National Health and Medical Research Council grant.
“FightMND is proud to support this important research,’’ Cure Research Manager Dr Michelle Kouspou said.
“At FightMND we call motor neurone disease the Beast, and it takes a combined effort from people all over the world to defeat a beast like this.”
“We look forward to seeing this research advance and bringing us closer to better treatments for people living with the disease.’’
Fighting the Beast takes a global effort
UQ biomedical scientist Associate Professor Richard Clark said the research findings were only possible through the combined expertise at UQ and its international partners.
“This global effort demonstrates the power of cross-disciplinary and cross-border collaboration in tackling complex biomedical challenges,” Dr Clark said.
“With this new ability to selectively target the C5aR2 receptor, we can develop safer, more effective drugs with fewer side effects.’’
The research was funded by FightMND and a National Health and Medical Research Council grant.
“FightMND is proud to support this important research,’’ Cure Research Manager Dr Michelle Kouspou said.
“At FightMND we call motor neurone disease the Beast, and it takes a combined effort from people all over the world to defeat a beast like this.”
“We look forward to seeing this research advance and bringing us closer to better treatments for people living with the disease.’’
This content was provided by The University of Queensland. The editorial staff of The Chronicle had no role in its preparation. Find out more about paid content.


